Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (471-480 of 688) with videos related to

Pageof 69
Sort By:
Diabetes, Obesity & Metabolism|October 10, 2023
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysisNikolaos Perakakis, Stefan R Bornstein, Andreas L Birkenfeld, et al.
JACC. Heart Failure|March 14, 2021
Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF TrialStephen J Greene, Eric J Velazquez, Kevin J Anstrom, et al.
European Journal of Heart Failure|March 18, 2017
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trialArnaud Olivier, Bertram Pitt, Nicolas Girerd, et al.
ESC Heart Failure|January 13, 2021
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trialCorrado De Marco, Brian L Claggett, Simon de Denus, et al.
Journal of Hypertension|December 30, 2022
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetesRajiv Agarwal, Luis M Ruilope, Gema Ruiz-Hurtado, et al.
European Heart Journal|April 22, 2025
Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programmeJoão Pedro Ferreira, Stefan D Anker, Biff F Palmer, et al.
Circulation. Heart Failure|January 28, 2010
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studiesC Barrett Bowling, Bertram Pitt, Mustafa I Ahmed, et al.
Pharmacological Research|October 4, 2016
Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the futurePatrick Rossignol, Matthieu Legrand, Mikhail Kosiborod, et al.
European Journal of Heart Failure|November 1, 2019
Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trialSergio H R Ramalho, Brian L Claggett, Nancy K Sweitzer, et al.
The American Journal of Medicine|September 22, 2018
Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection FractionEssraa Bayoumi, Phillip H Lam, Daniel J Dooley, et al.
Pageof 69

Showing results (471-480 of 688) with videos related to

Sort By:
Pageof 69
Diabetes, Obesity & Metabolism|October 10, 2023
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysisNikolaos Perakakis, Stefan R Bornstein, Andreas L Birkenfeld, et al.
JACC. Heart Failure|March 14, 2021
Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF TrialStephen J Greene, Eric J Velazquez, Kevin J Anstrom, et al.
European Journal of Heart Failure|March 18, 2017
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trialArnaud Olivier, Bertram Pitt, Nicolas Girerd, et al.
ESC Heart Failure|January 13, 2021
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trialCorrado De Marco, Brian L Claggett, Simon de Denus, et al.
Journal of Hypertension|December 30, 2022
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetesRajiv Agarwal, Luis M Ruilope, Gema Ruiz-Hurtado, et al.
European Heart Journal|April 22, 2025
Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programmeJoão Pedro Ferreira, Stefan D Anker, Biff F Palmer, et al.
Circulation. Heart Failure|January 28, 2010
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studiesC Barrett Bowling, Bertram Pitt, Mustafa I Ahmed, et al.
Pharmacological Research|October 4, 2016
Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the futurePatrick Rossignol, Matthieu Legrand, Mikhail Kosiborod, et al.
European Journal of Heart Failure|November 1, 2019
Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trialSergio H R Ramalho, Brian L Claggett, Nancy K Sweitzer, et al.
The American Journal of Medicine|September 22, 2018
Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection FractionEssraa Bayoumi, Phillip H Lam, Daniel J Dooley, et al.
Pageof 69